| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0002-9149(83)90310-7 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:0002914983903107?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:0002914983903107?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 6342353 |
| P2093 | author name string | W. A. Pettinger | |
| J. R. Corbett | |||
| B. G. Firth | |||
| A. Gilmore | |||
| R. V. Markham | |||
| P2860 | cites work | Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure | Q34300145 |
| Effects of prazosin on forearm resistance and capacitance vessels | Q39581745 | ||
| Drug therapy. Prazosin | Q39783482 | ||
| Clinical, hemodynamic, and neuroendocrine effects of chronic prazosin therapy for congestive heart failure | Q40084974 | ||
| Effect of prazosin vs placebo on chronic left ventricular heart failure | Q40976709 | ||
| Paradox of improved exercise but not resting hemodynamics with short-term prazosin in chronic heart failure | Q41474233 | ||
| Left ventricular volumes by gated equilibrium radionuclide angiography: a new method | Q41675497 | ||
| Plasma renin activity and plasma concentrations of norepinephrine and cyclic nucleotides in heart failure after prazosin | Q42244971 | ||
| Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure | Q42273273 | ||
| Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure | Q43573197 | ||
| Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man | Q44183533 | ||
| Attenuation of Prazosin Effect on Cardiac Output in Chronic Heart Failure | Q44360072 | ||
| Nongeometric determination of left ventricular volumes from equilibrium blood pool scans. | Q52436533 | ||
| Renin suppression by DOC and NaCl in the rat. | Q52737011 | ||
| Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. | Q54518104 | ||
| Improved right ventricular function and reduced pulmonary vascular resistance during prazosin therapy of congestive heart failure. | Q54534164 | ||
| Ambulatory prazosin treatment of chronic congestive heart failure: Development of late tolerance reversible by higher dosage and interrupted substitution therapy | Q54535863 | ||
| Development of pharmacodynamic tolerance to prazosin in congestive heart failure | Q54565545 | ||
| Comparison of effects of nitroprusside and prazosin on left ventricular function and the peripheral circulation in chronic refractory congestive heart failure | Q54589977 | ||
| Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure | Q67265268 | ||
| Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure | Q67285247 | ||
| Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output | Q67374006 | ||
| A simplified radiometric assay for plasma norepinephrine and epinephrine | Q68659734 | ||
| Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo | Q70259924 | ||
| Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure | Q70301317 | ||
| Direct measurement of cardiac output by gated equilibrium blood pool scintigraphy: Validation of scintigraphic volume measurements by a nongeometric technique | Q70749214 | ||
| Influence of oral prazosin therapy on exercise hemodynamics in patients with severe chronic heart failure | Q70815720 | ||
| Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure | Q71128688 | ||
| Left ventricular performance in normal subjects: a comparison of the responses to exercise in the upright and supine positions | Q71263183 | ||
| Effect of chronic oral digoxin therapy on ventricular function at rest and peak exercise in patients with ischemic heart disease | Q71322396 | ||
| Long-term therapy of heart failure with prazosin: a randomized double blind trial | Q71493978 | ||
| Vasodilator therapy in refractory congestive heart failure: a comparative analysis of hemodynamic and noninvasive studies | Q71587602 | ||
| Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure | Q71600790 | ||
| Assessment of vasodilator therapy in patients with severe congestive heart failure: Limitations of measurements of left ventricular ejection fraction and volumes | Q72962779 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| congestive heart failure | Q19000661 | ||
| Cardiology and cardiovascular medicine | Q96320350 | ||
| P304 | page(s) | 1346-1352 | |
| P577 | publication date | 1983-05-01 | |
| P1433 | published in | American Journal of Cardiology | Q2208417 |
| P1476 | title | Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study | |
| Efficacy of prazosin in the management of chronic congestive heart failure: A 6-month randomized, double-blind, placebo-controlled study | |||
| P478 | volume | 51 |
| Q24794338 | A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy |
| Q41941455 | Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure |
| Q38185737 | Alpha-adrenergic blockers. |
| Q54162416 | Double-Blind, Placebo-Controlled Study of the Long-term Efficacy of Carvedilol in Patients With Severe Chronic Heart Failure |
| Q68290032 | Doxazosin for the treatment of chronic congestive heart failure: Results of a randomized double-blind and placebo-controlled study |
| Q40093173 | Drugs and the heart four years on. |
| Q37932385 | Early intervention in heart failure |
| Q39468649 | Effect of drug therapy on survival in chronic congestive heart failure |
| Q70076966 | Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure |
| Q34621376 | Enalapril in heart failure |
| Q45099460 | Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure |
| Q54465894 | Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. |
| Q95817911 | Measurement of the quality of life in congestive heart failure-Influence of drug therapy |
| Q36764392 | Muscle metaboreflex-induced coronary vasoconstriction limits ventricular contractility during dynamic exercise in heart failure |
| Q41845098 | Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach |
| Q34398404 | Relationship between positive inotropic responses and plasma concentrations of xamoterol in middle-aged and elderly patients |
| Q54432369 | Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. |
| Q39543930 | The multifacetted role of angiotensin converting enzyme inhibitors in congestive heart failure |
| Q39764418 | The role of vasodilator therapy in the treatment of severe chronic heart failure |
| Q69617275 | The search of an ideal oral positive inotropic agent |
| Q39506159 | The treatment of heart failure. A methodological review of the literature |
| Q34487586 | Treatment of chronic heart failure: a review of recent drug trials |
| Q40091787 | Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism |
| Q38215916 | Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations |
Search more.